Prana Biotechnology Ltd. (PRAN)

1.99
0.00 (0.00)
NASDAQ : Health Technology
Prev Close 1.99
Open 1.90
Day Low/High 1.90 / 1.99
52 Wk Low/High 1.75 / 3.79
Volume 390.00
Avg Volume 68.20K
Exchange NASDAQ
Shares Outstanding 8.90M
Market Cap 16.38M
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Prana To Commence Phase 1 Clinical Trial Of PBT434 For Treatment Of Parkinsonian Diseases

Prana To Commence Phase 1 Clinical Trial Of PBT434 For Treatment Of Parkinsonian Diseases

Prana Biotechnology Ltd (ASX PBT: NASDAQ PRAN) is pleased to announce it has received ethics committee approval and has commenced recruitment for its Phase I Clinical trial evaluating the safety, tolerability and pharmacokinetics of the Company's lead...

Prana Commences Research Collaboration With Takeda For The Treatment Of Parkinson's Disease Gastrointestinal Neuropathology

Prana Commences Research Collaboration With Takeda For The Treatment Of Parkinson's Disease Gastrointestinal Neuropathology

Prana Biotechnology Ltd (ASX:PBT)(NASDAQ:PRAN) today announced a research collaboration with Takeda Pharmaceuticals International, Inc.

Prana's PBT434 Lowers Alpha-Synuclein And Prevents Neurodegeneration

Prana's PBT434 Lowers Alpha-Synuclein And Prevents Neurodegeneration

Prana Biotechnology Ltd (NASDAQ: PRAN) (ASX: PBT) today announced the article " The novel compound PBT434 prevents iron-mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease" was...

These 5 Stocks Under $10 Could Make You a Lot of Money

These 5 Stocks Under $10 Could Make You a Lot of Money

Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.

New Data From Reach2HD Trial Presented At American Neurological Association Annual Meeting

New Data From Reach2HD Trial Presented At American Neurological Association Annual Meeting

Prana Biotechnology Ltd (ASX:PBT/NASDAQ:PRAN) is pleased to announce that further analysis of the cognitive results of its Reach2HD trial to treat Huntington Disease was presented in a poster 1 at the American Neurological...

Prana Alzheimer's Disease Data Features At World Leading Conference

Prana Alzheimer's Disease Data Features At World Leading Conference

Professor Rudolph Tanzi, Founding Scientist and Chief Scientific Advisor for Prana Biotechnology, presented results obtained from testing PBT2, Prana's lead candidate for Huntington and Alzheimer's diseases, at the...

Prana Regains Compliance With NASDAQ Continued Listing Requirements Continues To Work Towards FDA Submission

Prana Regains Compliance With NASDAQ Continued Listing Requirements Continues To Work Towards FDA Submission

Prana Biotechnology Ltd (ASX:PBT)(NASDAQ:PRAN) today announced that it has received a notice dated April 8 th 2016 from the Listing Qualifications Department of NASDAQ Stock Market Inc.

Prana Biotechnology Half Year Investor Report

Prana Biotechnology Half Year Investor Report

Prana Biotechnology (ASX:PBT/NASDAQ:PRAN) has released its half year investor report for the six months to December 31, 2015.

Prana Chief Scientific Advisor Receives Smithsonian American Ingenuity Award

Prana Chief Scientific Advisor Receives Smithsonian American Ingenuity Award

Prana Biotechnology Limited (ASX:PBT/NASDAQ:PRAN) is pleased to congratulate its Chief Scientist, Professor Rudy Tanzi, who has been awarded a Smithsonian American Ingenuity Award for his work researching Alzheimer's...

Anavex Presents Meaningless Results in Alzheimer's Drug Study

Anavex Presents Meaningless Results in Alzheimer's Drug Study

'The chance you would have gotten similar data giving the patients 10 cups of coffee a day instead? Almost 100%,' said Dr. Adam Kline, a researcher who reviewed the data.

Prana Receives Non-Compliance Notice Regarding NASDAQ Minimum Bid Price Requirement

Prana Receives Non-Compliance Notice Regarding NASDAQ Minimum Bid Price Requirement

Prana Biotechnology Limited (ASX:PBT/NASDAQ:PRAN) has received notification from the Listing Qualifications Department of NASDAQ advising the Company that it is currently non-compliant with NASDAQ's requirement that listed...

Prana Reports FY15 Financial Results

Prana Reports FY15 Financial Results

Prana Biotechnology Limited (ASX:PBT) (NASDAQ:PRAN) yesterday announced its financial results for the 12 months to June 30, 2015.

Prana Announces Safety Outcomes Of Alzheimer's IMAGINE Extension Trial

Prana Announces Safety Outcomes Of Alzheimer's IMAGINE Extension Trial

Prana Biotechnology (ASX:PBT) (NASDAQ:PRAN) has today announced the safety outcomes of the IMAGINE Extension study in patients with Alzheimer's disease.

European Commission Approves PBT2 Orphan Designation For Huntington's Disease

European Commission Approves PBT2 Orphan Designation For Huntington's Disease

Prana Biotechnology Limited (ASX:PBT/NASDAQ:PRAN) has today announced that the European Commission has approved orphan designation for PBT2 for the treatment of Huntington's disease, stating that Prana has shown that PBT2...

PBT2 Recommended For Orphan Designation In Europe

PBT2 Recommended For Orphan Designation In Europe

Prana Biotechnology (ASX:PBT) (NASDAQ:PRAN) is pleased to announce the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending designation of PBT2 for the...

4 Stocks Under $10 to Trade for Big Breakouts

4 Stocks Under $10 to Trade for Big Breakouts

These under-$10 stocks are within range of triggering breakout trades.

The Lancet Neurology Publishes Prana's Huntington Disease Trial

The Lancet Neurology Publishes Prana's Huntington Disease Trial

Prana Biotechnology (ASX:PBT)(NASDAQ:PRAN) has today announced the results of its Phase 2 trial in Huntington Disease, REACH2HD, has been published online in one of the world's leading medical journals, The Lancet...

Why Prana Biotechnology (PRAN) Stock Is Surging Today

Why Prana Biotechnology (PRAN) Stock Is Surging Today

Shares of Prana Biotechnology (PRAN) soared 26.17% to $2.70 in morning trading Friday after the company announced the FDA granted Orphan Drug designation to PBT2 to treat Huntington Disease.

3 Biotech Stocks Under $10 in Breakout Territory

3 Biotech Stocks Under $10 in Breakout Territory

These under-$10 biotech stocks are within range of triggering breakout trades.

Why Prana Biotechnology (PRAN) Stock Is Surging Today

Why Prana Biotechnology (PRAN) Stock Is Surging Today

Prana Biotechnology (PRAN) surged Thursday after the company announced a new sub-analysis of its failed study Phase II of PBT2 in Alzheimer's disease.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look ready to break out and trade higher from current levels.

5 Stocks Under $10 Setting Up to Soar

5 Stocks Under $10 Setting Up to Soar

These under-$10 stocks look poised to break out and trade higher from current levels.

4 Stocks Under $10 to Trade for Breakouts

4 Stocks Under $10 to Trade for Breakouts

These under-$10 stocks are within range of triggering breakout trades.

3 Stocks Under $10 Making Big Moves

3 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Here's the Next Small-Cap Stock the Spec Money Will Chase

Here's the Next Small-Cap Stock the Spec Money Will Chase

Speculative money has returned to the markets with a vengeance in the small-cap arena.

Prana Biotechnology (PRAN) Stock Suddenly Surges

Prana Biotechnology (PRAN) Stock Suddenly Surges

Prana Biotechnology (PRAN) is surging today despite a lack of any significant news regarding the company, which develops drugs to treat neurodegenerative diseases.

A Beaten-Down Biotech Stock Poised to Perk Up

A Beaten-Down Biotech Stock Poised to Perk Up

The biotech sector is back in vogue today. Keep this beaten-down biotech stock on your radar.